American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma

References

• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011;365:474-5
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Moulopoulos L, et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 2013;27:947-53
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013;369:438-47
   PubMed Web of Science ®Google Scholar
• Mateos MV. Long term follow-up on the treatment of high risk smoldering myeloma with lenalidomide plus low dose dex (Rd) (phase III Spanish trial): persistent benefit in overall survival. Blood 2014;124:3465
   Web of Science ®Google Scholar
• Landgren carfilzomib, lenalidomide, and dexamethasone in high-risk smoldering multiple Myeloma: final results from the NCI Phase II pilot study. Blood 2014;124:4746
   Google Scholar
• Paiva B. Defining the differentiation stage of multiple myeloma plasma cells: biological and clinical significance. Blood 2014;124:25
   Google Scholar
• Paiva B. Clinical significance of sensitive flow-MRD monitoring in elderly multiple myeloma patients on the pethema/GEM2010MAS65 trial. Blood 2014;124:3390
   Google Scholar
• Gambella M. In multiple myeloma, minimal residual disease (MRD) is an early predictor of progression and is modulated by maintenance therapy with lenalidomide. Blood 2014;124:3394
   Google Scholar
• Rawstron minimal residual disease (MRD) in Myeloma: independent outcome prediction and sequential survival benefits per log tumour reduction. Blood 2014;124:3416
   Google Scholar
• Richardson P. Final Results for the 1703 Phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple Myeloma. Blood 2014;124:302
   Web of Science ®Google Scholar
• Stewart AK. Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients (Pts) with relapsed multiple Myeloma: interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study. Blood 2014;124:79
   Google Scholar
• Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008;112:1329-37
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142-52
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840-8
   PubMed Web of Science ®Google Scholar
• Plesner T. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Blood 2014;124:84
   PubMed Web of Science ®Google Scholar
• Martin TG. A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple Myeloma. Blood 2014;124:83
   Google Scholar
• Vij R. Clinical profile of single-agent oprozomib in patients (Pts) with multiple myeloma (MM): updated results from a multicenter, open-label, dose escalation Phase 1b/2 Study. Blood 2014;124:34
   Web of Science ®Google Scholar
• Kumar S. Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (Pts) with previously untreated multiple myeloma (MM): phase 2 Study Results. Blood 2014;124:82
   Web of Science ®Google Scholar
• Mateos MV. Comparison of sequential vs alternating administration of bortezomib, melphalan, prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly pts with newly diagnosed multiple Myeloma (MM) patients: GEM2010MAS65 trial. Blood 2014;124:178
   Web of Science ®Google Scholar
• Boyle EM. Mutational patterns and copy number changes at diagnosis are a powerful tool to predict outcome: result of the sequencing study of 463 newly diagnosed myeloma trial patients. Blood 2014;124:637
   Google Scholar